Inventor · disambiguated record
Scot Richard Mente
Also filed as: MENTE SCOT · MENTE SCOT R · MENTE SCOT RICHARD
32 granted patents·20 pending applications·104 citations·filing 2011–2025
96Inventor score
Top patents by PatentIndex Score
52 records- 0196US11299484B2Inhibiting fatty acid synthase (FASN)FORMA THERAPEUTICS INC·Filed 2020·Granted Apr 12, 2022·3 cites·22 claims
- 0294US11542278B1Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2021·Granted Jan 3, 2023·4 cites·30 claims
- 0394US9107923B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Aug 18, 2015·11 cites·30 claims
- 0493US11667649B2Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2021·Granted Jun 6, 2023·3 cites·31 claims
- 0593US9527831B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2014·Granted Dec 27, 2016·13 cites·30 claims
- 0693US9139561B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Sep 22, 2015·8 cites·30 claims
- 0791US9822097B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2016·Granted Nov 21, 2017·6 cites·15 claims
- 0890US8822494B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2013·Granted Sep 2, 2014·12 cites·54 claims
- 0989US9688698B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Jun 27, 2017·4 cites·20 claims
- 1089US2024317713A1Heteroaromatic compounds and their use as dopamine d1 ligandsPFIZER·Filed 2024·Application pending·0 cites
- 1188US11247987B2Inhibiting ubiquitin specific peptidase 30FORMA THERAPEUTICS INC·Filed 2018·Granted Feb 15, 2022·3 cites·24 claims
- 1287US9617275B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Apr 11, 2017·5 cites·18 claims
- 1387US9133190B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2014·Granted Sep 15, 2015·8 cites·60 claims
- 1486US12037346B2Amino-substituted heteroaryls for treating cancers with EGFR mutationsNUVALENT INC·Filed 2022·Granted Jul 16, 2024·1 cites·43 claims
- 1586US10093655B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2017·Granted Oct 9, 2018·3 cites·20 claims
- 1684US10421744B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2018·Granted Sep 24, 2019·2 cites·20 claims
- 1783US9670201B2Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereofPFIZER·Filed 2015·Granted Jun 6, 2017·3 cites·14 claims
- 1882US10875848B2Inhibiting fatty acid synthase (FASN)FORMA THERAPEUTICS INC·Filed 2019·Granted Dec 29, 2020·1 cites·30 claims
- 1982US10426135B2Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereofPFIZER·Filed 2019·Granted Oct 1, 2019·2 cites·7 claims
- 2082US9527843B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Dec 27, 2016·3 cites·14 claims
- 2179US9856263B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Jan 2, 2018·2 cites·16 claims
- 2278US2024352037A1Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2024·Application pending·0 cites
- 2377US11964961B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2021·Granted Apr 23, 2024·0 cites·20 claims
- 2477US10227346B2Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therofPFIZER·Filed 2018·Granted Mar 12, 2019·1 cites·4 claims
- 2574US12054498B2Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2022·Granted Aug 6, 2024·0 cites·48 claims
- 2674US11014909B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2020·Granted May 25, 2021·0 cites·22 claims
- 2774US10696658B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2019·Granted Jun 30, 2020·0 cites·13 claims
- 2873US12275742B2Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2022·Granted Apr 15, 2025·0 cites·31 claims
- 2973US2022315565A1Inhibiting fatty acid synthase (fasn)FORMA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3072US2024327435A1Amino-substituted heterocycles for treating cancers with egfr mutationsNUVALENT INC·Filed 2024·Application pending·0 cites
- 3171US9868744B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Jan 16, 2018·1 cites·14 claims
- 3271US8536164B2Fused pyridine compounds as casein kinase inhibitorsBUTLER TODD W·Filed 2011·Granted Sep 17, 2013·3 cites·10 claims
- 3370US10385036B2Sulfonamide-substituted indole modulators of RORC2 and methods of use thereofPFIZER·Filed 2016·Granted Aug 20, 2019·1 cites·13 claims
- 3468US10336748B2Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereofPFIZER·Filed 2016·Granted Jul 2, 2019·1 cites·11 claims
- 3568US2025382304A1Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2025·Application pending·0 cites
- 3667US2022185806A1Inhibiting ubiquitin specific peptidase 30FORMA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3767US2020039960A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2019·Application pending·0 cites
- 3865US2019144429A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2019·Application pending·0 cites
- 3965US2019387710A1Methyl- and Trifluromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use ThereofPFIZER·Filed 2019·Application pending·0 cites
- 4063US2016046597A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2014·Application pending·0 cites
- 4163US2018282304A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2018·Application pending·0 cites
- 4262US2017165270A1Heteroaromatic Compounds and their Use as Dopamine D1 LigandsPFIZER·Filed 2017·Application pending·0 cites
- 4362US2018086736A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2017·Application pending·0 cites
- 4462US2015291625A1Heteroaromatic Compounds and their Use as Dopamine D1 LigandsPFIZER·Filed 2013·Application pending·0 cites
- 4560US2018200253A1Heteroaromatic Compounds and their Use as Dopamine D1 LigandsPFIZER·Filed 2018·Application pending·0 cites
- 4660US2017233371A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2017·Application pending·0 cites
- 4757US2018346477A1Heteroaromatic compounds and their use as dopamine d1 ligandsPFIZER·Filed 2018·Application pending·0 cites
- 4856US10077272B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2017·Granted Sep 18, 2018·0 cites·19 claims
- 4954US2021346356A1Inhibiting ubiquitin specific peptidase 9xFORMA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 5048US2022041597A1Inhibiting ubiquitin specific peptidase 9xFORMA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →